Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators
- 1 September 2019
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 370 (3) , 447-458
Abstract
Recently we have shown the glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide (Lir), inhibits early atherosclerosis development in vivo by modulating immune cell function. We hypothesized Lir could attenuate pre-established disease by modulating monocyte/macrophage phenotype to induce athero-protective responses. Human atherosclerotic plaques obtained post-endarterectomy and human peripheral blood macrophages were treated ex vivo with Lir. In parallel, apolipoprotein E deficient (ApoE-/-) mice received a high-fat, high-cholesterol diet to induce atherosclerosis for 8 weeks, after which ApoE-/- mice received 300μg/kg Lir daily or vehicle control, for a further 4 weeks to investigate attenuation of atherosclerosis. Lir inhibited pro-inflammatory monocyte chemoattractant protein-1 (MCP-1) secretion from human endarterectomy samples and, MCP-1, tumour necrosis factor-alpha (TNF-α) and interleukin-1beta secretion from human macrophages following ex vivo treatment. An increase in CD206 mRNA and IL-10 secretion was also detected which imply resolution of inflammation. Importantly, Lir significantly attenuated pre-established atherosclerosis in ApoE-/- mice in the whole aorta and aortic root. Proteomic analysis of ApoE-/- bone marrow cells showed Lir up-regulated the pro-inflammatory cathepsin protein family, which was abolished in differentiated macrophages. In addition, flow cytometry analysis of bone marrow cells induced a shift towards reduced pro-inflammatory and increased anti-inflammatory macrophages. Lir attenuates pre-established atherosclerosis in vivo via altering pro-inflammatory mediators. This is the first study to describe a mechanism through which Lir attenuates atherosclerosis by increasing bone marrow pro-inflammatory protein expression, which is lost in differentiated bone marrow-derived macrophages. This contributes to our understanding of the anti-inflammatory and cardio-protective role of GLP-1RAs. SIGNIFICANCE STATEMENT It is critical to understand the mechanisms through which liraglutide (Lir) mediates a cardioprotective effect as many type 2 diabetic medications increase the risk of myocardial infarction and stroke. We have identified that Lir reduces pro-inflammatory immune cell populations and mediators from plaque-burdened murine aortas in vivo and augments proresolving bone marrow-derived macrophages in attenuation of atherosclerotic disease, which provides further insight into the athero-protective effect of Lir.Keywords
This publication has 28 references indexed in Scilit:
- An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathyDiabetologia, 2013
- IL‐10 mediates the immunoregulatory response in conjugated linoleic acid‐induced regression of atherosclerosisThe FASEB Journal, 2012
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activationBiochemical and Biophysical Research Communications, 2012
- Regression of Atherosclerosis Is Characterized by Broad Changes in the Plaque Macrophage TranscriptomePLOS ONE, 2012
- Insulin Resistance, Hyperglycemia, and AtherosclerosisCell Metabolism, 2011
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout miceDiabetologia, 2011
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse modelDiabetes & Vascular Disease Research, 2011
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4Diabetes, 2010
- Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese MiceDiabetes, 2009
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993